AstraZeneca's fostamatinib limps along in RA
This article was originally published in Scrip
Executive Summary
Having previously failed to outshine Abbott's Humira (adalimumab) in the monotherapy stakes, newly released data still suggest that AstraZeneca's new rheumatoid arthritis (RA) drug, fostamatinib, is lagging against other competitors in terms of efficacy and adverse events.